189 related articles for article (PubMed ID: 26211591)
1. Biological evaluation of a novel Herceptin-platinum (II) conjugate for efficient and cancer cell specific delivery.
Huang R; Sun Y; Zhang XY; Sun BW; Wang QC; Zhu J
Biomed Pharmacother; 2015 Jul; 73():116-22. PubMed ID: 26211591
[TBL] [Abstract][Full Text] [Related]
2. Trastuzumab-mediated selective delivery for platinum drug to HER2-positive breast cancer cells.
Huang R; Sun Y; Gao Q; Wang Q; Sun B
Anticancer Drugs; 2015 Oct; 26(9):957-63. PubMed ID: 26186063
[TBL] [Abstract][Full Text] [Related]
3. Herceptin-platinum(II) binding complexes: novel cancer-cell-specific agents.
Gao J; Liu YG; Liu R; Zingaro RA
ChemMedChem; 2008 Jun; 3(6):954-62. PubMed ID: 18366039
[TBL] [Abstract][Full Text] [Related]
4. Herceptin conjugated PLGA-PHis-PEG pH sensitive nanoparticles for targeted and controlled drug delivery.
Zhou Z; Badkas A; Stevenson M; Lee JY; Leung YK
Int J Pharm; 2015 Jun; 487(1-2):81-90. PubMed ID: 25865568
[TBL] [Abstract][Full Text] [Related]
5. Injectable hydrogels for the sustained delivery of a HER2-targeted antibody for preventing local relapse of HER2+ breast cancer after breast-conserving surgery.
Chen X; Wang M; Yang X; Wang Y; Yu L; Sun J; Ding J
Theranostics; 2019; 9(21):6080-6098. PubMed ID: 31534538
[TBL] [Abstract][Full Text] [Related]
6. Targeting HER2-positive cancer with dolastatin 15 derivatives conjugated to trastuzumab, novel antibody-drug conjugates.
Gianolio DA; Rouleau C; Bauta WE; Lovett D; Cantrell WR; Recio A; Wolstenholme-Hogg P; Busch M; Pan P; Stefano JE; Kramer HM; Goebel J; Krumbholz RD; Roth S; Schmid SM; Teicher BA
Cancer Chemother Pharmacol; 2012 Sep; 70(3):439-49. PubMed ID: 22821053
[TBL] [Abstract][Full Text] [Related]
7. Specific drug delivery efficiently induced human breast tumor regression using a lipoplex by non-covalent association with anti-tumor antibodies.
Lin YL; Tsai NM; Chen CH; Liu YK; Lee CJ; Chan YL; Wang YS; Chang YC; Lin CH; Huang TH; Wang CC; Chi KH; Liao KW
J Nanobiotechnology; 2019 Feb; 17(1):25. PubMed ID: 30728015
[TBL] [Abstract][Full Text] [Related]
8. A new application of plant virus nanoparticles as drug delivery in breast cancer.
Esfandiari N; Arzanani MK; Soleimani M; Kohi-Habibi M; Svendsen WE
Tumour Biol; 2016 Jan; 37(1):1229-36. PubMed ID: 26286831
[TBL] [Abstract][Full Text] [Related]
9. Herceptin-functionalized pure paclitaxel nanocrystals for enhanced delivery to HER2-postive breast cancer cells.
Noh JK; Naeem M; Cao J; Lee EH; Kim MS; Jung Y; Yoo JW
Int J Pharm; 2016 Nov; 513(1-2):543-553. PubMed ID: 27686050
[TBL] [Abstract][Full Text] [Related]
10. Trastuzumab-cisplatin conjugates for targeted delivery of cisplatin to HER2-overexpressing cancer cells.
Huang R; Wang Q; Zhang X; Zhu J; Sun B
Biomed Pharmacother; 2015 May; 72():17-23. PubMed ID: 26054670
[TBL] [Abstract][Full Text] [Related]
11. Reduced in vivo lung metastasis of a breast cancer cell line after treatment with Herceptin mAb conjugated to chemotherapeutic drugs.
Garcia AG; Nedev H; Bijian K; Su J; Alaoui-Jamali MA; Saragovi HU
Oncogene; 2013 May; 32(20):2527-33. PubMed ID: 22797066
[TBL] [Abstract][Full Text] [Related]
12. Tumor targeting using polyamidoamine dendrimer-cisplatin nanoparticles functionalized with diglycolamic acid and herceptin.
Kesavan A; Ilaiyaraja P; Sofi Beaula W; Veena Kumari V; Sugin Lal J; Arunkumar C; Anjana G; Srinivas S; Ramesh A; Rayala SK; Ponraju D; Venkatraman G
Eur J Pharm Biopharm; 2015 Oct; 96():255-63. PubMed ID: 26277659
[TBL] [Abstract][Full Text] [Related]
13. Upregulated HSP27 in human breast cancer cells reduces Herceptin susceptibility by increasing Her2 protein stability.
Kang SH; Kang KW; Kim KH; Kwon B; Kim SK; Lee HY; Kong SY; Lee ES; Jang SG; Yoo BC
BMC Cancer; 2008 Oct; 8():286. PubMed ID: 18834540
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and properties of a new micellar polyphosphazene-platinum(II) conjugate drug.
Avaji PG; Joo HI; Park JH; Park KS; Jun YJ; Lee HJ; Sohn YS
J Inorg Biochem; 2014 Nov; 140():45-52. PubMed ID: 25061690
[TBL] [Abstract][Full Text] [Related]
15. Ablation of breast cancer cells using trastuzumab-functionalized multi-walled carbon nanotubes and trastuzumab-diphtheria toxin conjugate.
Oraki Kohshour M; Mirzaie S; Zeinali M; Amin M; Said Hakhamaneshi M; Jalili A; Mosaveri N; Jamalan M
Chem Biol Drug Des; 2014 Mar; 83(3):259-65. PubMed ID: 24118702
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
[TBL] [Abstract][Full Text] [Related]
17. The co-delivery of paclitaxel and Herceptin using cationic micellar nanoparticles.
Lee AL; Wang Y; Cheng HY; Pervaiz S; Yang YY
Biomaterials; 2009 Feb; 30(5):919-27. PubMed ID: 19042015
[TBL] [Abstract][Full Text] [Related]
18. Combination of adoptive immunotherapy with Herceptin for patients with HER2-expressing breast cancer.
Kubo M; Morisaki T; Kuroki H; Tasaki A; Yamanaka N; Matsumoto K; Nakamura K; Onishi H; Baba E; Katano M
Anticancer Res; 2003; 23(6a):4443-9. PubMed ID: 14666732
[TBL] [Abstract][Full Text] [Related]
19. [Herceptin-based therapy for breast cancer].
Tokuda Y; Saito Y; Suzuki Y
Nihon Rinsho; 2006 Mar; 64(3):540-5. PubMed ID: 16529047
[TBL] [Abstract][Full Text] [Related]
20. Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer.
Zhang JL; Yao Q; Chen Y Wang JH; Wang H; Fan Q; Ling R; Yi J; Wang L
Genet Mol Res; 2015 Mar; 14(1):2099-103. PubMed ID: 25867356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
